Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Updates in metastatic prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 2964

Prof Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou, Prof Nicolas Mottet

Professor Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou and Professor Nicolas Mottet discuss the management of patients with metastatic hormone sensitive prostate cancer (mHSPC) and the anticipated impact the data presented at the 2018 ASCO Genitourinary Cancers Symposium will have on the management of this patient group.

They discuss how data presented over the last few years has changed the approach to management of patients with mHSPC.

The conversation also focuses on how to best stratify patients and whether volume of disease impacts treatment decisions.

The panel discuss the disease features and patient charactistics that influence choice of therapy for patients with hormones sensitive disease and the importance of a shared discussion between patients and clinicians when making these treatment decisions.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation